{ "docId": "019dd923-622c-750b-8b9a-21918ac10c17", "docSlug": "f3db2294dcf9", "documentTitle": "Harmony Biosciences (HRMY)", "authorId": "58_Scorpion_Capital", "authorName": "Scorpion Capital", "documentKindSlug": "research-note", "documentKindLabel": "Research note", "sourceTypeSlug": "short_seller", "sourceTypeLabel": "Short seller", "presentationDate": "2023-03-28 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 97, "pageCount": 366, "prevPage": 96, "nextPage": 98, "slideType": "expose_contradiction", "function": "expose_contradiction", "density": "dense", "nDataPoints": 0, "notes": "The slide uses highlighted text to emphasize key claims about compound quality and pharmacokinetic challenges.", "elementsJson": [ "paragraph", "quote_block", "footnote" ], "metadataConfidence": 1, "imagePath": null, "slideHref": "/slides/019dd923-622c-750b-8b9a-21918ac10c17/97", "deckHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17", "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17.json", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17#slide-97", "components": [ { "bbox": null, "kind": "callout", "text": "We had much better compounds based on physical property and drug-like properties than pitolisant. So, we pursued those.", "attrs": null, "subkind": null, "toolName": "Visual emphasis", "toolSlug": "visual-emphasis", "confidence": null, "componentId": "019dd953-64d0-7099-9cd0-5980c45cd349", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.05, "w": 0.86, "x": 0.07, "y": 0.31 }, "kind": "paragraph", "text": "JNJ compounds were better than pitolisant but “for every company that got into this, the pharmacokinetics presented a challenge”", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "06239dc6-5a92-41db-98f4-0a97abf2d898", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.35, "w": 0.86, "x": 0.07, "y": 0.37 }, "kind": "paragraph", "text": "Q: “What did you mean by your statement that the compounds that you came up with were better than pitolisant?”\nA: “We wanted compounds where we drove everything off target engagement. So, we wanted to know what exposure you needed to get target engagement centrally for activity. And we also wanted to understand the pharmacokinetics, and for every company that got into this, the pharmacokinetics presented a challenge. The pharmacokinetic behavior is how the body treats the drug. So, what you need for this type of drug is a compound with a relatively short half-life. That’s because it’s a pro-arousal; it keeps people awake. And we actually published and presented the data, whereas if your compound half-life is too long, you’re going to keep people awake for days. And so, the concern is that you want a compound with a relatively short half-life that you can give once a day. And for every company, it was a challenge. So, we got fairly close to that; other companies got pretty close to that, that they could take the compounds in the clinic. But we also measured central engagement in the brain, and we did that with positron emission studies. We used a PET ligand in healthy volunteers to find out what dose do we have to give to get central occupancy for this receptor in the brain..”–Longtime senior scientist at Johnson & Johnson, with global leadership roles in neuroscience", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "3dfbd3c8-7908-4fbd-9849-171af0fedda3", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.2, "w": 0.86, "x": 0.07, "y": 0.73 }, "kind": "paragraph", "text": "JNJ was intimately familiar with pitolisant but had “much better compounds”\n“We were aware of pitolisant. It wasn’t called pitolisant when we got into this. We had much better compounds based on physical property and drug-like properties than pitolisant. So, we pursued those. And we had compounds that were good enough to take into a number of clinical trials, which are in clinicaltrials.gov…So, I am familiar with the pitolisant structure. That actually came from a collaboration between Bioprojet and a bunch of European investigators, the Free University of Berlin, and the University College London. Very simple compound.” –Longtime senior scientist at Johnson & Johnson, with global leadership roles in neuroscience", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "413cb4a3-9506-488d-b93c-219b3617ed81", "frameworkName": null, "frameworkSlug": null }, { "bbox": null, "kind": "quote", "text": "“I am familiar with the pitolisant structure”; “very simple compound”; “we had much better compounds based on physical property and drug-like properties than pitolisant. So, we pursued those.” — Longtime senior scientist at Johnson & Johnson", "attrs": null, "subkind": null, "toolName": "Authority citation", "toolSlug": "authority-citation", "confidence": null, "componentId": "019dd953-64d0-7099-9cd0-5ce02b2c5427", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.03, "w": 0.3, "x": 0.07, "y": 0.95 }, "kind": "source-note", "text": "Source: Scorpion Capital consultation calls with experts", "attrs": null, "subkind": null, "toolName": null, "toolSlug": null, "confidence": null, "componentId": "459c610b-00b2-47d7-9356-5f90be95d5f2", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.18, "w": 0.86, "x": 0.07, "y": 0.07 }, "kind": "title", "text": "He indicated that J&J’s H3 receptor compounds were far better than pitolisant, based on their testing: “I am familiar with the pitolisant structure”; “very simple compound”; “we had much better compounds based on physical property and drug-like properties than pitolisant. So, we pursued those.” He added that “for every company that got into this, the pharmacokinetics presented a challenge” – echoing the same color provided to us by the ex-Abbott scientist.", "attrs": null, "subkind": "headline", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "fd57a39c-45cf-4ba6-bc16-14f327b62a08", "frameworkName": null, "frameworkSlug": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }